Mechanism studies
Payarmin Science & Clinical Dossier
Payarmin has no published trial of its own. This dossier grades the human research on each ingredient and compares the doses used there with what one 1 mL dropper can hold.
Clinical takeaways
- Payarmin itself has no published human trial; every study here tested an ingredient on its own, usually at a far higher dose.
- Chromium is the only itemized active, at 0.7 mcg. Trials used 200 to 1,000 mcg and still found small, inconsistent effects on glucose.
- Gymnema, green tea and Panax ginseng have the most glucose-relevant human data in the blend; none has a disclosed amount.
- Lifestyle programs like the Diabetes Prevention Program remain the strongest evidence for preventing type 2 diabetes.
How to read a mechanism dossier for a 22-ingredient blend
A sales page can name a pathway for every ingredient: insulin signalling for chromium, sugar-taste blocking for gymnema, catechins for green tea, ginsenosides for ginseng. Each of those pathways is real biology. The question a dossier has to answer is narrower: did people taking this ingredient, at a stated dose, see a measurable change in fasting glucose, post-meal glucose or A1C? And is the dose in the bottle anywhere near that? We grade every claim on both.
The answer for Payarmin is constrained by its label. Chromium is printed at 0.7 mcg. The other 22 entries share 200 mg. That ceiling matters more than any mechanism, because most of the human research below used hundreds of milligrams to several grams of a single ingredient.
Chromium: the itemized active
Chromium helps insulin act on cells, which is why it appears in almost every blood-sugar formula. The NIH Office of Dietary Supplements sets an Adequate Intake of 25 to 35 mcg a day for adults, and notes that most people get that from food.[1] Trials that tested chromium for glucose control used 200 to 1,000 mcg. A 2016 review in Nutrition Reviews concluded the evidence of benefit in type 2 diabetes is limited,[2] and a 2014 meta-analysis found modest fasting-glucose reductions with wide variation between trials.[3] In overweight adults without diabetes, a systematic review found effects too small to matter clinically.[4] At 0.7 mcg a dropper, Payarmin supplies about 2% of the Daily Value, roughly one three-hundredth of the lowest trial dose.
Gymnema: the most relevant herb, with no stated amount
Gymnema leaf contains gymnemic acids that blunt sweet taste and may reduce sugar absorption. A 1990 study gave 400 mg a day of a standardized extract to people with type 2 diabetes alongside their medication and reported lower fasting glucose and A1C over 18 to 20 months.[5] A 2021 meta-analysis pooled later trials and found improvements in fasting glucose, with the caveat that study quality was mixed.[6] The label gives no standardization percentage for the gymnema in Payarmin and no amount, and it sits eighth in the blend order.
Green tea and Panax ginseng
A meta-analysis of 17 randomized trials found that green tea or its catechins lowered fasting glucose and A1C slightly, with the effect concentrated in higher-catechin preparations.[7] For ginseng, a 2014 meta-analysis of the Panax genus found a modest drop in fasting glucose, mostly from root extracts at gram doses.[8] Payarmin lists Panax ginseng aerial extract, the leaves and stems, which have a different ginsenoside profile from the root used in most trials.
African mango, glutamine and the dose gap
African mango seed (Irvingia) was tested in Cameroon at 150 mg twice a day for weight and metabolic markers;[9] a later systematic review judged those trials too small and flawed to support a recommendation.[10] L-glutamine raised GLP-1 and lowered post-meal glucose in one study at 15 g,[11] which is why GLP-1 appears in sales copy. GLP-1 is a real hormone with a real role,[12] but 15 g is 75 times the whole Payarmin blend.
What has stronger evidence than any of these
The Diabetes Prevention Program cut the progression from prediabetes to type 2 diabetes by 58% with diet, activity and modest weight loss,[13] and a simple habit, walking after meals, lowered post-meal glucose more than the same walk at other times.[14] If you are deciding where to put effort, those come first; a supplement is at best an add-on.
Evidence summary by ingredient group
| Group | Best human evidence | Dose in trials | In Payarmin |
|---|---|---|---|
| Chromium | Small, inconsistent glucose effects | 200 to 1,000 mcg | 0.7 mcg |
| Gymnema | Fasting glucose and A1C, mixed quality | About 400 mg extract | Undisclosed, under 200 mg |
| Green tea | Slight fasting glucose drop | Catechin extracts, varied | Undisclosed |
| Panax ginseng | Modest fasting glucose drop (root) | About 1 to 3 g | Aerial parts, undisclosed |
| African mango | Weight, weak trials | 300 mg | Undisclosed |
| Amino acids (7) | Not glucose at these doses | Grams | Undisclosed |
| Other botanicals (8) | Little or none for glucose | Varied | Undisclosed |
Continue with the formula architecture for each ingredient's form and safety notes, or the micronutrient synergy index for the chromium question in depth.
References
- 1NIH Office of Dietary Supplements. Chromium: Fact Sheet for Health Professionals.
- 2Costello RB, Dwyer JT, Bailey RL. Chromium supplements for glycemic control in type 2 diabetes: limited evidence of effectiveness. Nutr Rev. 2016;74(7):455-468.
- 3Suksomboon N, Poolsup N, Yuwanakorn A. Systematic review and meta-analysis of the efficacy and safety of chromium supplementation in diabetes. J Clin Pharm Ther. 2014;39(3):292-306.
- 4Onakpoya I, Posadzki P, Ernst E. Chromium supplementation in overweight and obesity: a systematic review and meta-analysis of randomized clinical trials. Obes Rev. 2013;14(6):496-507.
- 5Baskaran K, Kizar Ahamath B, Radha Shanmugasundaram K, Shanmugasundaram ER. Antidiabetic effect of a leaf extract from Gymnema sylvestre in non-insulin-dependent diabetes mellitus patients. J Ethnopharmacol. 1990;30(3):295-300.
- 6Devangan S, Varghese B, Johny E, et al. The effect of Gymnema sylvestre supplementation on glycemic control in type 2 diabetes patients: a systematic review and meta-analysis. Phytother Res. 2021;35(12):6802-6812.
- 7Liu K, Zhou R, Wang B, et al. Effect of green tea on glucose control and insulin sensitivity: a meta-analysis of 17 randomized controlled trials. Am J Clin Nutr. 2013;98(2):340-348.
- 8Shishtar E, Sievenpiper JL, Djedovic V, et al. The effect of ginseng (the genus Panax) on glycemic control: a systematic review and meta-analysis of randomized controlled clinical trials. PLoS One. 2014;9(9):e107391.
- 9Ngondi JL, Etoundi BC, Nyangono CB, Mbofung CM, Oben JE. IGOB131, a novel seed extract of the West African plant Irvingia gabonensis, significantly reduces body weight and improves metabolic parameters in overweight humans in a randomized double-blind placebo controlled investigation. Lipids Health Dis. 2009;8:7.
- 10Onakpoya I, Davies L, Posadzki P, Ernst E. The efficacy of Irvingia gabonensis supplementation in the management of overweight and obesity: a systematic review of randomized controlled trials. J Diet Suppl. 2013;10(1):29-38.
- 11Samocha-Bonet D, Wong O, Synnott EL, et al. Glutamine reduces postprandial glycemia and augments the glucagon-like peptide-1 response in type 2 diabetes patients. J Nutr. 2011;141(7):1233-1238.
- 12Drucker DJ. Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell Metab. 2018;27(4):740-756.
- 13Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346(6):393-403.
- 14Reynolds AN, Mann JI, Williams S, Venn BJ. Advice to walk after meals is more effective for lowering postprandial glycaemia in type 2 diabetes mellitus than advice that does not specify timing: a randomised crossover study. Diabetologia. 2016;59(12):2572-2578.